EVFM — Evofem Biosciences, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1618835 ·
Last close
$0.00
Market Cap
$569.9K
52W High
$0.01
52W Low
$0.00
ADV30
162,759
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 2,633,000 | 2,122,000 | -2,489,000 | -11,036,000 | 7,522,000 | — | 95,038,000 |
| Mar 2026 | 899,000 | 489,000 | -4,569,000 | -5,465,000 | 7,442,000 | 1,491,000 | 85,072,000 |
| Dec 2025 | 9,561,000 | 6,969,000 | 3,345,000 | 2,788,000 | 20,274,000 | — | 94,610,000 |
| Sep 2025 | 4,952,000 | 4,047,000 | -982,000 | -1,569,000 | 13,807,000 | 0 | 88,873,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-472,000
Investing CF
$-5,000
Financing CF
$14,000
CapEx
$-5,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.14
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-914,019,000
Inventory
$2,155,000
Receivables
$2,685,000
ST Investments
—
EBIT TTM
$-4,695,000
Pretax Income TTM
$-15,288,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$18,045,000
EBITDA
$-4,420,000
Free Cash Flow
$6,408,750
Enterprise Value
$60,227,480
Total Cash
$144,000
Total Debt
$54,325,000
Shares Out
132,530,081
Trailing EPS
$-0.11
Book Value
$-0.66
ROE
—
ROA
-26.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 20,183,000 | 1,439,000 | 391,000 | 20,274,000 | 94,610,000 | -74,336,000 | -1,992,000 |
| Dec 2024 | 19,363,000 | -7,676,000 | -8,860,000 | 23,789,000 | 95,046,000 | -71,257,000 | -3,885,000 |
| Dec 2023 | 18,218,000 | -17,847,000 | 52,979,000 | 10,600,000 | 77,100,000 | -66,510,000 | -8,968,000 |
| Dec 2022 | 16,837,000 | -84,124,000 | -76,698,000 | 25,200,000 | 96,963,000 | -71,800,000 | -70,410,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$7,522,000
Forward EPS
$-0.55
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BIOM | BIOMOLECULAR LIFE HOLDINGS, INC. | $580.8K | $0.50 | — |
| LABT | Lakewood-Amedex Biotherapeutics Inc. | $508.3K | $0.21 | — |
| VBIO | Valion Bio, Inc. | $482.3K | $0.54 | — |
| CYTOF | Altamira Therapeutics Ltd. | $405.8K | $0.07 | — |
| PTIX | Protagenic Therapeutics, Inc.\new | $814.6K | $0.45 | — |
News headlines (Yahoo Finance, 1h cache)
Quarterly Profit Could Change The Case For Evofem Biosciences Stock
2026-11-18 08:10 · Yahoo
HUB Cyber Security Expands Into Women’s Health With Zero-Cash Acquisition of Evofem Notes, Advances Balance Sheet Turnaround
2026-07-01 11:00 · Yahoo
Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE
2025-11-21 14:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.